Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population

Yann Neuzillet, Xavier Tillou, Romain Mathieu, Jean Alexandre Long, Marc Gigante, Philippe Paparel, Laura Poissonnier, Hervé Baumert, Bernard Escudier, Hervé Lang, Nathalie Rioux-Leclercq, Pierre Bigot, Jean Christophe Bernhard, Laurence Albiges, Laurence Bastien, Jacques Petit, Fabien Saint, Franck Bruyere, Jean Michel Boutin, Nicolas BrichartGeorges Karam, Julien Branchereau, Jean Marie Ferriere, Hervé Wallerand, Sébastien Barbet, Hicham Elkentaoui, Jacques Hubert, Benoit Feuillu, Pierre Etienne Theveniaud, Arnauld Villers, Laurent Zini, Aurélien Descazeaux, Morgan Roupret, Benoit Barrou, Karim Fehri, Thierry Lebret, Jacques Tostain, Jean Etienne Terrier, Nicolas Terrier, Lucille Martin, Fabrice Dugardin, Ismaël Galliot, Frédéric Staerman, Marie Dominique Azemar, Jacques Irani, Baptiste Tisserand, Marc Olivier Timsit, Federico Sallusto, Pascal Rischmann, Laurent Guy, Antoine Valeri, Charles Deruelle, Abdel Rahmne Azzouzi, Denis Chautard, Arnaud Mejean, Laurent Salomon, Jérôme Rigaud, Christian Pfister, Michel Soulié, Franois Kleinclauss, Lionel Badet, Jean Jacques Patard

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    77 Citations (Scopus)

    Résumé

    Background: Patients with end-stage renal disease (ESRD) are at risk of developing renal tumours. Objective: Compare clinical, pathologic, and outcome features of renal cell carcinomas (RCCs) in ESRD patients and in patients from the general population. Design, setting, and participants: Twenty-four French university departments of urology participated in this retrospective study. Intervention: All patients were treated according to current European Association of Urology guidelines. Measurements: Age, sex, symptoms, tumour staging and grading, histologic subtype, and outcome were recorded in a unique database. Categoric and continuous variables were compared by using chi-square and student statistical analyses. Cancer-specific survival (CSS) was assessed by Kaplan-Meier and Cox methods. Results and limitations: The study included 1250 RCC patients: 303 with ESRD and 947 from the general population. In the ESRD patients, age at diagnosis was younger (55 ± 12 yr vs 62 ± 12 yr); mean tumour size was smaller (3.7 ± 2.6 cm vs 7.3 ± 3.8 cm); asymptomatic (87% vs 44%), low-grade (68% vs 42%), and papillary tumours were more frequent (37% vs 7%); and poor performance status (PS; 24% vs 37%) and advanced T categories (≥3) were more rare (10% vs 42%). Consistently, nodal invasion (3% vs 12%) and distant metastases (2% vs 15%) occurred less frequently in ESRD patients. After a median follow-up of 33 mo (range: 1-299 mo), 13 ESRD patients (4.3%), and 261 general population patients (27.6%) had died from cancer. In univariate analysis, histologic subtype, symptoms at diagnosis, poor PS, advanced TNM stage, high Fuhrman grade, large tumour size, and non-ESRD diagnosis context were adverse predictors for survival. However, only PS, TNM stage, and Fuhrman grade remained independent CSS predictors in multivariate analysis. The limitation of this study is related to the retrospective design. Conclusions: RCC arising in native kidneys of ESRD patients seems to exhibit many favourable clinical, pathologic, and outcome features compared with those diagnosed in patients from the general population.

    langue originaleAnglais
    Pages (de - à)366-373
    Nombre de pages8
    journalEuropean Urology
    Volume60
    Numéro de publication2
    Les DOIs
    étatPublié - 1 août 2011

    Contient cette citation